TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE:MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has filed its final short form base shelf prospectus (the "Prospectus") to provide the Company with the flexibility to take advantage of financing opportunities and favourable market conditions, if and when needed, during the 25-month period that the Prospectus remains effective (the "Effective Period"). A copy of the Prospectus may be obtained under the Company's SEDAR+ profile at www.sedarplus.ca.

The Prospectus has been filed in each of the provinces and territories in Canada. The Prospectus will enable the Company to offer, issue and sell, from time to time, common shares, warrants, units, subscription receipts, debt securities, or any combination of such securities (collectively, "Securities").

The Company may also use the Prospectus in connection with an "at-the-market distribution" in accordance with applicable securities laws, which would permit the Securities to be sold on behalf of the Company through the Canadian Securities Exchange (the "CSE") (or other existing trading markets) as further described in the applicable prospectus supplement. To date, no agreement has been entered into with respect to such a distribution.

PharmAla currently has no immediate plans to issue any Securities under the Prospectus at this time and may never proceed with any such issuance. Should the Company decide to offer Securities, the specific terms, including the use of proceeds, will be set forth in a prospectus supplement to the final base shelf prospectus, which will be filed with the applicable Canadian securities regulators.

PharmAla Signs Term Sheet with Radium Capital

PharmAla is furthermore pleased to announce that its subsidiary, PharmAla Biotech Australia Pty Ltd ("PharmAla Australia"), has signed a term sheet with Radium Capital ("Radium"), providing PharmAla Australia with a loan facility leveraging its estimated Research and Development Tax Incentive ("RDTI") refunds. As PharmAla Australia has not yet commenced operations in Australia, no tranches of the RDTI loan facility have been drawn upon. Once PharmAla Australia has commenced to incur qualifying expenses, Radium will advance ...